» Articles » PMID: 15323151

ACE Inhibitors and Target Organ Protection. An Expanded Role for These Antihypertensive Agents?

Overview
Journal Postgrad Med
Publisher Informa Healthcare
Specialty General Medicine
Date 2004 Aug 25
PMID 15323151
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Lowering the risk of cardiovascular disease (CVD) involves more than treatment of individual risk factors such as hypertension, diabetes, and chronic kidney disease. In this article, Drs Toto, Rinner, and Ram present an evidence-based approach to reducing CVD risk and suggest that optimal treatment with angiotensin-converting enzyme (ACE) inhibitors should be extended to a larger proportion of at-risk patients and in particular to those not previously considered candidates for use of these agents.

Citing Articles

Complex Relationship Between Cardiac Fibroblasts and Cardiomyocytes in Health and Disease.

Hall C, Gehmlich K, Denning C, Pavlovic D J Am Heart Assoc. 2021; 10(5):e019338.

PMID: 33586463 PMC: 8174279. DOI: 10.1161/JAHA.120.019338.


Fixed combination of zofenopril plus hydrochlorothiazide in the management of hypertension: a review of available data.

Borghi C, Cicero A Vasc Health Risk Manag. 2007; 2(4):341-9.

PMID: 17323587 PMC: 1994025. DOI: 10.2147/vhrm.2006.2.4.341.


Zofenopril plus hydrochlorothiazide: Combination therapy for the treatment of mild to moderate hypertension.

Zanchetti A, Parati G, Malacco E Drugs. 2006; 66(8):1107-15.

PMID: 16789795 DOI: 10.2165/00003495-200666080-00006.


Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy.

Ofili E, Ferdinand K, Saunders E, Neutel J, Bakris G, Cushman W J Natl Med Assoc. 2006; 98(4):618-26.

PMID: 16623075 PMC: 2569215.